As major players in healthcare, drug companies are constantly impacted by, and influencing, trends in the marketplace. This is an ever-changing environment affecting product access, and we’re here to keep you sharp. Subscribe below to stay in the know.

    Privacy Guaranteed — We will never share your info

    • The Increasing Exploitation of Patient Assistance Programs

      Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On top of that, providers face the difficulty of helping patients manage a process they...
    • Fractures in The 340B Program

      The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps them in business. Pharma...
    • The Impact of Medicare Price Negotiations

      The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law's anticipated impact. Here is a summary...
    • The Part D Squeeze

      [DISCLAIMER: This isn’t a legal analysis. We’ve simplified provisions in the law where we could while still describing the intent of the law]The Inflation Reduction Act (IRA) will have broad implications across the healthcare...
    • “Negotiating” A Drug Deal with Medicare

      [DISCLAIMER: This isn’t a legal analysis. We’ve simplified provisions in the law where we could while still describing the intent of the law]The newly-signed Inflation Reduction Act (IRA) that allows Medicare to negotiate drug...
    • Shopping for Healthcare Deals

      New price transparency rules set by the government are an opportunity to save money. Not for hospitals, not for payers, but for you and me. Isn’t that a nice change of pace?What’s changed?There are...
    • Are PBMs Actually Pharma’s Friends?

      Pharmacy Benefit Managers (PBMs) have received a lot of negative publicity lately. Here is some more: A new whistleblower lawsuit has opened another door that reveals more skeletons in the PBM’s closet. Does this...
    • A 3-way Tug-of-War Over Physician Practices

      and its impact on pharmaPhysicians who own their own practices should feel honored! They are the focus of an ongoing tug-of-war between the biggest stakeholders in the healthcare industry. The prize in this contest...
    • Biosimilars Are Gaining Ground

      In 2010, the Affordable Care Act defined a process intended to introduce competition to biologic drugs. For years, generic competition to brand name drugs has been successful in driving overall drug costs down. Are...
    • Primary Care: A Symphony or a Cacophony?

      Your simple act of walking into a primary care office sets off a series of events orchestrated by unseen conductors. Is this a good thing? The process used to be simple; your primary care physician...
    Specializing in training and consulting on trends in the healthcare marketplace impacting market access

    Market Access Training Solutions

    Manufacturers Restricting 340B Sales to Contract Pharmacies

    • Abbvie
    • Amgen
    • AstraZeneca
    • Boehringer Ingelheim
    • Eli Lilly
    • Merck
    • Novartis
    • Novo Nordisk
    • Sanofi
    • UCB
    • United Therapeutics
    • and more…